InvestorsHub Logo
Followers 45
Posts 3487
Boards Moderated 0
Alias Born 05/26/2011

Re: None

Wednesday, 12/01/2021 12:01:47 PM

Wednesday, December 01, 2021 12:01:47 PM

Post# of 118423
rgbp... While our IP is just being licensed lately, it will take quite a while before they obtain the 50 to 100 licensees necessary to challenge the top 5 in the field? Then each of the top 5 most likely have 10 to 20 products being used regularly by the Medical establishment! It'll be quite a dog fight for any of our products to butt heads, and win, with other products which have been used for a long time!

Just look at Novartis, who have a few products out there, and have their latest prodigious product, ENTRESTO, a promising CONGESTIVE HEART FAILURE Drug, having been out in the public for a couple of years, yet few Medical establishment entities use it a main source of treatment, like at the VA, where conditions have to be just right before they can use it as a treatment! The VA tends to use compounds that have been tried and tested in all areas, and though they haven't been that effective as treatments, they are used even though they tend to ONLY halt the progression of CHF, and are not curative treatments at all? The new drug from Novartis, ENTRESTO, has far more curative potential, yet gets little attention from the practitioners who use Heart drugs at a certain hospital I know of, and at the VA Hospital, but are far short of being Treatments! While the Hospitals I speak of have rigid standards, which often makes the best treatments unavailable until one is near death, and the other Drugs are found to be not capable of dealing with more serious cases! Then ENTRESTO jumps in as another alternative! Then being used at a later stage of the disease, there is a greater chance of not fulfilling the promise it holds by showing faults and problems due to being used so late? GLTA